Regen BioPharma, Inc. Files New Composition of Matter Patent Application Based on Its Successful Modulation of NR2F6 by Its Small Molecule Compounds

SAN DIEGO, September 6, 2018 /PRNewswire/ --

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has filed a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate NR2F6 ("Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans").

As previously noted by the Company, NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Based upon the Company's screening programs for treating autoimmune diseases such as Lupus, the data gathered provided support for the filing of this patent application.

Additionally, the Company is moving forward with its NR2F6 antagonist small molecule program designed to unleash the cancer-killing potential of a patient's own immune system.

"The patent application lists molecules that activate NR2F6. As we continue to develop our small molecule program, we learn more about the molecular structures key to activating NR2F6 and develop more optimized compounds," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "Thus, we continue to file for patent protection for these unique molecules."

David Koos, Ph.D., CEO of Regen BioPharma, Inc., added, "We continue to ensure the intellectual property that is generated by Regen is protected so that our shareholders can materially benefit from the commercialization of this technology."

About Regen BioPharma Inc.:  

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION

Regen BioPharma Inc.
David R. Koos, Ph.D.

Chairman & Chief Executive Officer

+1-619-702-1404 Phone

+1-619-330-2328 Fax
http://www.regenbiopharma.com
[email protected]

SOURCE Regen BioPharma, Inc.